• Discovery of novel candidates for anti- liposarcoma therapies by medium-scale high-throughput drug screening 

      Grad, Iwona; Hanes, Robert; Ayuda-Durán, Pilar; Kuijjer, Marieke Lydia; Enserink, Jorrit; Meza-Zepeda, Leonardo A; Myklebost, Ola (Journal article; Peer reviewed, 2021)
      Sarcomas are a heterogeneous group of mesenchymal orphan cancers and new treatment alternatives beyond traditional chemotherapeutic regimes are much needed. So far, tumor mutation analysis has not led to significant treatment ...
    • miR-486-5p expression is regulated by DNA methylation in osteosarcoma 

      Namløs, Heidi Maria; Skårn, Magne Nordang; Ali, Deeqa Ahmed Mohamed; Grad, Iwona; Andresen, Kim; Kresse, Stine Henrichson; Munthe, Else; Serra, Massimo; Scotlandi, Katia; Llombart-Bosch, Antonio; Myklebost, Ola; Lind, Guro Elisabeth; Meza, Leonardo Zepeda (Journal article; Peer reviewed, 2022)
      Background Osteosarcoma is the most common primary malignant tumour of bone occurring in children and young adolescents and is characterised by complex genetic and epigenetic changes. The miRNA miR-486-5p has been shown ...
    • Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma 

      Hanes, Robert; Munthe, Else; Grad, Iwona; Han, Jianhua; Karlsen, Ida Tveit; Mc Cormack, Emmet; Meza-Zepeda, Leonardo A.; Stratford, Eva Wessel; Myklebost, Ola (Peer reviewed; Journal article, 2019-02-21)
      Background: FGFR inhibition has been proposed as treatment for dedifferentiated liposarcoma (DDLPS) with amplified FRS2, but we previously only demonstrated transient cytostatic effects when treating FRS2-amplified DDLPS ...